Shopping Cart 0
Cart Subtotal
USD 0

North America Cancer Screening Market (2018-2023)

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 1950
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

North America cancer screening market

North America is leading the cancer screening market. The region is technologically equipped and being a developed economy it is efficiently catering to the rising incidence of cancer cases. The market is forecasted to grow at a compound annual growth rate (CAGR) f 11.14% resulting in an annual revenue of USD 16.36 Bn during the forecast period 2018-2023.

Companies are focusing on research & development (R&D) and entering into collaborations with the government to expand regional access.

By end users, the market is segmented into hospitals, laboratories and independent physicians and clinics. The Laboratory segment will witness a progressive growth during the forecast period 2018-2023 while the hospital segment will account for the maximum revenue of USD 11.18 billion during the forecast period.

By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Genetic and biopsy will be the leading segments during the forecast period 2018-2023.

By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Colorectal, kidney, melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.

By countries, the market is divided into the United States Of America (U.S.A.) , Canada and others (the rest of North America).

Key growth factors

The rising incidence of cancer cases has led to a growing need among people to seek early cure and diagnosis. Technological advancements being adopted at a rapid pace to combat the rapid spread of cancer are the key growth factors for the market.

Threats and key players

The North America cancer screening market is a mature market for cancer screening and is forecasted to grow at a growth rate of 8.3%. But regulatory hindrances in the form of policies and norms which has the potential to impact the growth of the market.

Key players in the North America cancer screening market are GE Healthcare, Siemens Healthcare GmbH, Hologic Inc., Thermo Fisher Scientific, etc.

What is covered in the report?

1. Overview of the North America cancer screening market.

2. Market drivers and challenges in the North America cancer screening market.

3. Market trends in the North America cancer screening market.

4. Historical, current and forecasted market size data for the North America market segmentation based on type of end user (hospitals, laboratories , independent physicians and clinics)-by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) -by type of application (lung, breast, melanoma, kidney and colorectal)

5. Historical, current and forecasted market size data for the North America market segmentation based on type of end-user (hospitals, laboratories, independent physicians and clinics)-by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) -by type of application (lung, breast, melanoma, kidney and colorectal).

6. Historical, current and forecasted market size data of cancer screening market by countries U.S.A., Canada and others (the rest of North America)-by revenue.

7. Historical, current and forecasted market size data for country-wise segments-by revenue.

8. Analysis of the competitive landscape and profiles of major competitors operating in the North American market.

Why buy?

o Understand the demand for cancer screening market to determine the viability of the market.

o Understand the country-specific market size and observations for each segment.

o Develop strategies based on the drivers, trends and highlights for each of the segments.

o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.

o Recognize the key competitors of this market and respond accordingly.

o Identify the initiatives and growth strategies taken by the major companies and decide the direction of further growth.

o Define the competitive positioning by comparing the products and services compared with the key players in the market.

Customizations available

With the given market data, Netscribes offers customizations according to specific needs. Write to us at support@researchonglobalmarkets.com.

READ MORE

Table Of Content

Scope

Chapter 1: Executive summary

1.1 Market scope and segmentation

1.2 Key questions answered in this study

1.3 Executive summary

Chapter 2: North America cancer screening market-market overview

2.1. North America market overview-market trends, market attractiveness analysis, country-wise market revenue (USD)

2.2. North America-market drivers and challenges

2.3. Value chain analysis-cancer screening market

2.4. Porter's five forces analysis

2.5. Market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics)

2.5. a. Hospitals-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.5. b. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.5. c. Independent physicians and clinics revenue-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.5. d. Growth drivers and key challenges

2.6. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

2.6. a. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.6. b. Genetic-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.6. c. Imaging-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.6. d. Biopsy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.6. e. Endoscopy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.6. f. Growth drivers and key challenges

2.7. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

2.7. a. Lung-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.7. b. Breast-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.7. c. Melanoma-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.7. d. Kidney-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.7. e. Colorectal-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.7. f. Growth drivers and key challenges

2.8. Major country penetration

Chapter 3. The USA cancer screening market

3.1. The USA market overview-market trends, market attractiveness analysis, country-wise market revenue (USD)

3.2. Market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics)

3.2. a. Hospitals-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.2. b. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.2. c. Independent physicians and clinics revenue-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.2. d. Growth drivers and key challenges

3.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

3.3. a. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. b. Genetic-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. c. Imaging-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. d. Biopsy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. e. Endoscopy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. f. Growth drivers and key challenges

3.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

3.4. a. Lung-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.4. b. Breast-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.4. c. Melanoma-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.4. d. Kidney-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.4. e. Colorectal-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.4. f. Growth drivers and key challenges

Chapter 4. Canada smart manufacturing industry 4.0 market

4.1. Canada market overview-market trends, market attractiveness analysis, country-wise market revenue (USD)

4.2. Market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics)

4.2. a. Hospitals-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.2. b. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.2. c. Independent physicians and clinics revenue-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.2. d. Growth drivers and key challenges

4.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

4.3. a. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.3. b. Genetic-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.3. c. Imaging-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.3. d. Biopsy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.3. e. Endoscopy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.3. f. Growth drivers and key challenges

4.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

4.4. a. Lung-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.4. b. Breast-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.4. c. Melanoma-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.4. d. Kidney-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.4. e. Colorectal-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.4. f. Growth drivers and key challenges

Chapter 5. Others (the rest of North America) smart manufacturing industry 4.0 market

5.1. Others (the rest of North America) market overview-market trends, market attractiveness analysis, country-wise market revenue (USD)

5.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)

5.2. a. Hospitals-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.2. b. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.2. c. Independent physicians and clinics revenue-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.2. d. Growth drivers and key challenges

5.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

5.3. a. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.3. b. Genetic-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.3. c. Imaging-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.3. d. Biopsy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.3. e. Endoscopy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.3. f. Growth drivers and key challenges

5.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

5.4. a. Lung-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.4. b. Breast-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.4. c. Melanoma-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.4. d. Kidney-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.4. e. Colorectal-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.4. f. Growth drivers and key challenges

Chapter 6: Competitive landscape

6.1. GE Healthcare

6.1. a. Company snapshot

6.1. b. Product offerings

6.1. c. Growth strategies

6.1. d. Initiatives

6.1. e. Geographical presence

6.1. f. Key numbers

6.2. Siemens Healthineers

6.2. a. Company snapshot

6.2. b. Product offerings

6.2. c. Growth strategies

6.2. d. Initiatives

6.2. e. Geographical presence

6.2. f. Key numbers

6.3. Hologic Inc.

6.3. a. Company snapshot

6.3. b. Product offerings

6.3. c. Growth strategies

6.3. d. Initiatives

6.3. e. Geographical presence

6.3. f. Key numbers

6.4. Thermo Fisher Scientific

6.4. a. Company snapshot

6.4. b. Product offerings

6.4. c. Growth strategies

6.4. d. Initiatives

6.4. e. Geographical presence

6.4. f. Key numbers

6.5. Roche Diagnostics

6.5. a. Company snapshot

6.5. b. Product offerings

6.5. c. Growth strategies

6.5. d. Initiatives

6.5. e. Geographical presence

6.5. f. Key numbers

Chapter 7: Conclusion

Chapter 8: Appendix

8.1. List of tables

8.2. Assumptions

8.3. Research and methodology

8.4. About Netscribes Inc.

Note: The Table of Contents (Toc) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research.

Disclaimer: The report will be delivered within 5-7 business days post payment confirmation

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

1. GE Healthcare

2. Siemens Healthcare GmbH

3. Hologic Inc.

4. Thermo Fisher Scientific

5. Roche Diagnostics

North America cancer screening market

North America is leading the cancer screening market. The region is technologically equipped and being a developed economy it is efficiently catering to the rising incidence of cancer cases. The market is forecasted to grow at a compound annual growth rate (CAGR) f 11.14% resulting in an annual revenue of USD 16.36 Bn during the forecast period 2018-2023.

Companies are focusing on research & development (R&D) and entering into collaborations with the government to expand regional access.

By end users, the market is segmented into hospitals, laboratories and independent physicians and clinics. The Laboratory segment will witness a progressive growth during the forecast period 2018-2023 while the hospital segment will account for the maximum revenue of USD 11.18 billion during the forecast period.

By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Genetic and biopsy will be the leading segments during the forecast period 2018-2023.

By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Colorectal, kidney, melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.

By countries, the market is divided into the United States Of America (U.S.A.) , Canada and others (the rest of North America).

Key growth factors

The rising incidence of cancer cases has led to a growing need among people to seek early cure and diagnosis. Technological advancements being adopted at a rapid pace to combat the rapid spread of cancer are the key growth factors for the market.

Threats and key players

The North America cancer screening market is a mature market for cancer screening and is forecasted to grow at a growth rate of 8.3%. But regulatory hindrances in the form of policies and norms which has the potential to impact the growth of the market.

Key players in the North America cancer screening market are GE Healthcare, Siemens Healthcare GmbH, Hologic Inc., Thermo Fisher Scientific, etc.

What is covered in the report?

1. Overview of the North America cancer screening market.

2. Market drivers and challenges in the North America cancer screening market.

3. Market trends in the North America cancer screening market.

4. Historical, current and forecasted market size data for the North America market segmentation based on type of end user (hospitals, laboratories , independent physicians and clinics)-by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) -by type of application (lung, breast, melanoma, kidney and colorectal)

5. Historical, current and forecasted market size data for the North America market segmentation based on type of end-user (hospitals, laboratories, independent physicians and clinics)-by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) -by type of application (lung, breast, melanoma, kidney and colorectal).

6. Historical, current and forecasted market size data of cancer screening market by countries U.S.A., Canada and others (the rest of North America)-by revenue.

7. Historical, current and forecasted market size data for country-wise segments-by revenue.

8. Analysis of the competitive landscape and profiles of major competitors operating in the North American market.

Why buy?

o Understand the demand for cancer screening market to determine the viability of the market.

o Understand the country-specific market size and observations for each segment.

o Develop strategies based on the drivers, trends and highlights for each of the segments.

o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.

o Recognize the key competitors of this market and respond accordingly.

o Identify the initiatives and growth strategies taken by the major companies and decide the direction of further growth.

o Define the competitive positioning by comparing the products and services compared with the key players in the market.

Customizations available

With the given market data, Netscribes offers customizations according to specific needs. Write to us at support@researchonglobalmarkets.com.

READ MORE

Scope

Chapter 1: Executive summary

1.1 Market scope and segmentation

1.2 Key questions answered in this study

1.3 Executive summary

Chapter 2: North America cancer screening market-market overview

2.1. North America market overview-market trends, market attractiveness analysis, country-wise market revenue (USD)

2.2. North America-market drivers and challenges

2.3. Value chain analysis-cancer screening market

2.4. Porter's five forces analysis

2.5. Market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics)

2.5. a. Hospitals-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.5. b. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.5. c. Independent physicians and clinics revenue-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.5. d. Growth drivers and key challenges

2.6. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

2.6. a. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.6. b. Genetic-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.6. c. Imaging-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.6. d. Biopsy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.6. e. Endoscopy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.6. f. Growth drivers and key challenges

2.7. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

2.7. a. Lung-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.7. b. Breast-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.7. c. Melanoma-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.7. d. Kidney-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.7. e. Colorectal-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

2.7. f. Growth drivers and key challenges

2.8. Major country penetration

Chapter 3. The USA cancer screening market

3.1. The USA market overview-market trends, market attractiveness analysis, country-wise market revenue (USD)

3.2. Market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics)

3.2. a. Hospitals-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.2. b. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.2. c. Independent physicians and clinics revenue-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.2. d. Growth drivers and key challenges

3.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

3.3. a. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. b. Genetic-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. c. Imaging-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. d. Biopsy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. e. Endoscopy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. f. Growth drivers and key challenges

3.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

3.4. a. Lung-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.4. b. Breast-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.4. c. Melanoma-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.4. d. Kidney-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.4. e. Colorectal-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.4. f. Growth drivers and key challenges

Chapter 4. Canada smart manufacturing industry 4.0 market

4.1. Canada market overview-market trends, market attractiveness analysis, country-wise market revenue (USD)

4.2. Market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics)

4.2. a. Hospitals-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.2. b. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.2. c. Independent physicians and clinics revenue-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.2. d. Growth drivers and key challenges

4.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

4.3. a. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.3. b. Genetic-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.3. c. Imaging-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.3. d. Biopsy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.3. e. Endoscopy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.3. f. Growth drivers and key challenges

4.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

4.4. a. Lung-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.4. b. Breast-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.4. c. Melanoma-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.4. d. Kidney-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.4. e. Colorectal-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.4. f. Growth drivers and key challenges

Chapter 5. Others (the rest of North America) smart manufacturing industry 4.0 market

5.1. Others (the rest of North America) market overview-market trends, market attractiveness analysis, country-wise market revenue (USD)

5.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)

5.2. a. Hospitals-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.2. b. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.2. c. Independent physicians and clinics revenue-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.2. d. Growth drivers and key challenges

5.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

5.3. a. Laboratory-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.3. b. Genetic-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.3. c. Imaging-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.3. d. Biopsy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.3. e. Endoscopy-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.3. f. Growth drivers and key challenges

5.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).

5.4. a. Lung-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.4. b. Breast-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.4. c. Melanoma-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.4. d. Kidney-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.4. e. Colorectal-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.4. f. Growth drivers and key challenges

Chapter 6: Competitive landscape

6.1. GE Healthcare

6.1. a. Company snapshot

6.1. b. Product offerings

6.1. c. Growth strategies

6.1. d. Initiatives

6.1. e. Geographical presence

6.1. f. Key numbers

6.2. Siemens Healthineers

6.2. a. Company snapshot

6.2. b. Product offerings

6.2. c. Growth strategies

6.2. d. Initiatives

6.2. e. Geographical presence

6.2. f. Key numbers

6.3. Hologic Inc.

6.3. a. Company snapshot

6.3. b. Product offerings

6.3. c. Growth strategies

6.3. d. Initiatives

6.3. e. Geographical presence

6.3. f. Key numbers

6.4. Thermo Fisher Scientific

6.4. a. Company snapshot

6.4. b. Product offerings

6.4. c. Growth strategies

6.4. d. Initiatives

6.4. e. Geographical presence

6.4. f. Key numbers

6.5. Roche Diagnostics

6.5. a. Company snapshot

6.5. b. Product offerings

6.5. c. Growth strategies

6.5. d. Initiatives

6.5. e. Geographical presence

6.5. f. Key numbers

Chapter 7: Conclusion

Chapter 8: Appendix

8.1. List of tables

8.2. Assumptions

8.3. Research and methodology

8.4. About Netscribes Inc.

Note: The Table of Contents (Toc) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research.

Disclaimer: The report will be delivered within 5-7 business days post payment confirmation

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

1. GE Healthcare

2. Siemens Healthcare GmbH

3. Hologic Inc.

4. Thermo Fisher Scientific

5. Roche Diagnostics